𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Eli Lilly and Company CEO Dave A Ricks discusses GLP-1's, Alzheimer's, business development, and more. Full video:

@EliLillyandCo @DaveARicks He looks super young, must be in his own medicine. I love Mounjaro

@EliLillyandCo @DaveARicks As an $LLY investor, I'd like to see plans to add additional sarcopenia assets to the pipeline (e.g., GPR133/ADGRD1 agonists like AP503).

@bradloncar @EliLillyandCo @DaveARicks Congrats Brad - great interview!

@EliLillyandCo @DaveARicks So far… the best interview ever and will be very hard to surpass 👌🏻

@EliLillyandCo @DaveARicks Kudos to you both. Great interview. Looking forward to the next one.

@EliLillyandCo @DaveARicks Credit to @DaveARicks for agreeing to do this interview. He comes across as unusually approachable, yet extremely articulate and competent. I will be looking further into the company's pipeline/increasing my position on the basis of this interview 👍🏼

@EliLillyandCo @DaveARicks Amazing interview. I wish this was another hour, or more. Kudos @bradloncar for a masterful job and thank you @DaveARicks for reading my tweet that started this all off 😂

@EliLillyandCo @DaveARicks Worth knowing about Lilly's oral GLP-1, orforglipron: it's a small molecule, not a peptide. In ATTAIN-1 (3,127 adults without diabetes, 72 wks) the top dose averaged −11.2% body weight vs −2.1% on placebo.